Recently Added

  • Omvoh (mirikizumab-mrkz)


    LILLY

    Omvoh Mirikizumab-Mrkz 300 Mg/15 Ml Infusion, 100 Mg/Ml Injection] Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis.

  • Zepbound® (tirzepatide) Injection, sponsored by Lilly USA, LLC


    ELI LILLY & CO.

    Zepbound® Is Indicated As An Adjunct To A Reduced-Calorie Diet And Increased Physical Activity For Chronic Weight Management In Adults With An Initial Body Mass Index (Bmi) Of: 30 Kg/M2 Or Greater (Obesity) Or 27 Kg/M2 Or Greater (Overweight) In The Presence Of At Least One Weight-Related Comorbid Condition (E.G., Hypertension, Dyslipidemia, Type 2 Diabetes Mellitus, Obstructive Sleep Apnea, Or Cardiovascular Disease

  • Injectafer® (ferric carboxymaltose injection), Sponsored by Daiichi Sankyo, Inc.


    AMER. REGENT

    Injectafer Is A Prescription Iron Replacement Medicine Administered Only By Or Under The Supervision Of Your Healthcare Provider. Injectafer Is Injected Into Your Vein To Treat Iron Deficiency Anemia In Adults And Pediatric Patients 1 Year Of Age And Older. Injectafer Should Be Used Only If You Have Not Responded Well To Treatment With Oral Iron, Or If You Are Intolerant To Oral Iron Treatment. It Is Also Used To Treat Iron Deficiency Anemia In Adults With Chronic Kidney Disease Who Are Not R

  • JEMPERLI (dostarlimab-gxly) sponsored by GSK


    GLAXOSMITHKLINE

    Jemperli, In Combination With Carboplatin And Paclitaxel, Followed By Jemperli As A Single Agent, Is Indicated For The Treatment Of Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer (Ec) That Is Mismatch Repair Deficient (Dmmr), As Determined By An Fda-Approved Test, Or Microsatellite Instability-High (Msi-H). Jemperli, As A Single Agent, Is Indicated For The Treatment Of Adult Patients With Dmmr Recurrent Or Advanced: Ec, As Determined By An Fda-Approved Test, That Has P

  • ABECMA® (idecabtagene vicleucel)


    BMS

    Abecma (Idecabtagene Vicleucel) Is A B-Cell Maturation Antigen (Bcma)-Directed Genetically Modified Autologous T Cell Immunotherapy Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Multiple Myeloma After Four Or More Prior Lines Of Therapy, Including An Immunomodulatory Agent, A Proteasome Inhibitor, And An Anti-Cd38 Monoclonal Antibody.

  • CABOMETYX® (cabozantinib) sponsored by Exelixis, Inc.


    EXELIXIS, INC.

    Indications Cabometyx® (Cabozantinib), In Combination With Nivolumab, Is Indicated For The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma (Rcc). Cabometyx Is Indicated For The Treatment Of Patients With Advanced Rcc. Cabometyx Is Indicated For The Treatment Of Patients With Hepatocellular Carcinoma (Hcc) Who Have Been Previously Treated With Sorafenib. Cabometyx Is Indicated For The Treatment Of Adult And Pediatric Patients 12 Years Of Age And Older With Local

  • APRETUDE (cabotegravir) by ViiV Healthcare


    VIIV HEALTHCARE

    Apretude Is Indicated In At-Risk Adults And Adolescents Weighing At Least 35 Kg For Pre-Exposure Prophylaxis (Prep) To Reduce The Risk Of Sexually Acquired Hiv-1 Infection. Individuals Must Have A Negative Hiv-1 Test Prior To Initiating Apretude (With Or Without An Oral Lead-In With Oral Cabotegravir) For Hiv-1 Prep.

  • NUCALA (mepolizumab) by GSK


    GLAXOSMITHKLINE

    Nucala Is An Interleukin-5 (Il-5) Antagonist Monoclonal Antibody (Igg1 Kappa) Indicated For: • Add-On Maintenance Treatment Of Adult And Pediatric Patients Aged 6 Years And Older With Severe Asthma And With An Eosinophilic Phenotype. • Add-On Maintenance Treatment Of Adult Patients 18 Years And Older With Chronic Rhinosinusitis With Nasal Polyps (Crswnp). • The Treatment Of Adult Patients With Eosinophilic Granulomatosis With Polyangiitis (Egpa). • The Treatment Of Adult And Pediatric Pat

  • TIBSOVO® (ivosidenib tablets) by Servier Pharmaceuticals


    AGIOS PHARMACEU

    Tibsovo Is Indicated For Patients With A Susceptible Isocitrate Dehydrogenase-1 (Idh1) Mutation As Detected By An Fda-Approved Test With: Newly Diagnosed Acute Myeloid Leukemia (Aml) In Combination With Azacitidine Or As Monotherapy For The Treatment Of Newly Diagnosed Aml In Adults 75 Years Or Older, Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy Relapsed Or Refractory Aml For The Treatment Of Adult Patients With Relapsed Or Refractory Aml Rela